, WHO, 2018.
Tuberculosis treatment and drug regimens. Cold Spring Harb Perspect Med 5: a017822, 2015. ,
, After the UNGA High-Level Meeting on Tuberculosis-what next and how? The Lancet Global Health, vol.7, pp.30068-30071, 2019.
Bedaquiline: first FDA-approved tuberculosis drug in 40 years, Int J Appl Basic Med Res, vol.3, pp.1-2, 2013. ,
Migliori GB and the writing group members of the Global TB Network Clinical Trials Committee (2019) Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives, Eur Respir Rev, vol.30, 190035. ,
Treatment for extreme drug-resistant tuberculosis wins US government approval, Nature, 2019. ,
Bedaquiline: first FDA-approved tuberculosis drug in 40 years, Int J Appl Basic Med Res, vol.3, pp.1-2, 2013. ,
The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis, Proc Natl Acad Sci, vol.105, pp.11945-11950, 2008. ,
Advent of Imidazo[1,2-a]pyridine-3-carboxamides with Potent Multi-and Extended Drug Resistant Antituberculosis Activity, ACS Med Chem Lett, vol.2, pp.466-470, 2011. ,
Advancement of Imidazo[1,2-a]pyridines with Improved Pharmacokinetics and Nanomolar Activity Against Mycobacterium tuberculosis, ACS Med Chem Lett, vol.4, pp.675-679, 2013. ,
Scaffold-switching: an exploration of 5,6-fused bicyclic heteroaromatics systems to afford antituberculosis activity akin to the imidazo [1,2-a]pyridine-3-carboxylates, Bioorg Med Chem Lett, vol.24, pp.3493-3498, 2014. ,
Bactericidal activity of an imidazo[1,2-a] pyridine using a mouse M. tuberculosis infection model, PLoS One, vol.9, 2014. ,
Putting Tuberculosis (TB) To Rest: Transformation of the Sleep Aid, Ambien, and "Anagrams" Generated Potent Antituberculosis Agents, ACS Infect Dis, vol.1, pp.85-90, 2015. ,
Imidazo[1,2-a]Pyridine-3-Carboxamides Are Active Antimicrobial Agents against Mycobacterium avium Infection In Vivo, Antimicrob Agents Chemother, vol.60, p.27216051, 2016. ,
A dual read-out assay to evaluate the potency of compounds active against Mycobacterium tuberculosis, PLoS One, vol.8, p.60531, 2013. ,
, Evaluation of Imidazo[2,1-b]thiazole-5-carboxamide Anti-Tubercular Tuberculosis Compound PLOS ONE |, 2020.
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis, Nat Med, vol.19, pp.1157-1160, 2013. ,
Lead optimization of a novel series of imidazo [1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi-and extensively-drug-resistant anti-tuberculosis agent, J Med Chem, vol.57, pp.5293-5305, 2014. ,
Identification of novel imidazo [1,2-a]pyridine inhibitors targeting M. tuberculosis QcrB, PLoS One, vol.7, 2012. ,
Imidazopyridine compounds inhibit mycobacterial growth by depleting ATP levels, Antimicrob Agents Chemother, vol.62, pp.2439-2456, 2018. ,
Lansoprazole is an antituberculous prodrug targeting cytochrome bc1, Nature Comm, vol.6, p.7659, 2015. ,
Arylvinylpiperazine Amides, a New Class of Potent Inhibitors Targeting QcrB of Mycobacterium tuberculosis, Mbio, vol.9, pp.1276-1294, 2018. ,
Identification of morpholino thiophenes as novel Mycobacterium tuberculosis inhibitors, targeting QcrB, J Med Chem, vol.61, pp.6592-6608, 2018. ,
Combinations of respiratory chain inhibitors have enhanced bactericidal activity against Mycobacterium tuberculosis, Antimicrob Agents Chemother, vol.62, pp.1677-1694, 2018. ,
Improved phenoxyalkylbenzimidazoles with activity against Mycobacterium tuberculosis appear to target QcrB, ACS Infect Dis, vol.3, pp.898-916, 2017. ,
Respiratory flexibility in response to inhibition of cytochrome C oxidase in Mycobacterium tuberculosis, Antimicrob Agents Chemother, vol.58, pp.6962-6965, 2014. ,
Arrival of Imidazo[2,1-b]thiazole-5-carboxamides: Potent Anti-tuberculosis Agents That Target QcrB, ACS Infect Dis, vol.2, pp.393-398, 2016. ,
Preparation and Evaluation of Potent Pentafluorosulfanyl-Substituted Anti-Tuberculosis Compounds, ChemMedChem, vol.12, pp.1108-1115, 2017. ,
Discovery of new chemical entities as potential leads against Mycobacterium tuberculosis, Bioorg Med Chem Lett, vol.26, pp.5916-5919, 2016. ,
Design, synthesis, and biological evaluation of pyrazolo[1,5-a]pyridine-3-carboxamides as novel antitubercular agents, ACS Med Chem Lett, vol.6, pp.814-818, 2015. ,
Pyrazolo[1,5-a]pyridine Inhibitor of the Respiratory Cytochrome bcc Complex for the Treatment of Drug-Resistant Tuberculosis, ACS Infect Dis, vol.5, pp.239-249, 2018. ,
Identification of Pyrazolo[1,5-a]pyridine-3-carboxamide Diaryl Derivatives as Drug Resistant Anti-tuberculosis Agents, ACS Med Chem Lett, vol.10, pp.295-299, 2019. ,
A microscopic phenotypic assay for the quantification of intracellular mycobacteria adapted for high-throughput/high-content screening, J Vis Exp, vol.83, p.51114, 2014. ,
Phenotypic assays for Mycobacterium tuberculosis infection, Cytometry A, vol.91, pp.983-994, 2017. ,
Growthcurver: an R package for obtaining interpretable metrics from microbial growth curves, BMC Bioinformatics, vol.17, p.27094401, 2016. ,
, Evaluation of Imidazo[2,1-b]thiazole-5-carboxamide Anti-Tubercular Tuberculosis Compound PLOS ONE |, 2020.
Low-Oxygen-Recovery Assay for highthroughput screening of compounds against nonreplicating Mycobacterium tuberculosis, Antimicrob Agents Chemother, vol.51, pp.1380-1385, 2007. ,
Nitrate reduction as a marker for hypoxic shiftdown of Mycobacterium tuberculosis, Tuber Lung Dis, vol.79, pp.127-132, 1998. ,
In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis, Antimicrob Agents Chemother, vol.49, pp.1447-1454, 2005. ,
High content phenotypic cell-based visual screen identifies Mycobacterium tuberculosis acyltrehalose-containing glycolipids involved in phagosome remodeling, PLoS Pathog, vol.6, 2010. ,
Preclinical testing of the nitroimidazopyran PA-824 for activity against M. tuberculosis in a series of in vitro and in vivo models, 2005. ,
, Antimicrob Agents Chemother, vol.49, pp.2294-2301
Thiolates chemically induce redox activation of BTZ043 and related potent nitroaromatic anti-tuberculosis agents, J Am Chem Soc, vol.135, pp.3539-3549, 2013. ,
Lead-and drug-like compounds: the rule-of-five revolution, Drug Discov Today Technol, vol.1, pp.337-341, 2004. ,
Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation, Drug Metab Dispos, vol.38, pp.981-987, 2010. ,
Oxidative Phosphorylation as a Target Space for Tuberculosis: Success, Caution, and Future Direction, Microbiol Spectr, vol.5, 2017. ,
Exploiting the synthetic lethality between terminal respiratory oxidases to kill Mycobacterium tuberculosis and clear host infection, 2017. ,
, Proc Natl Acad Sci, vol.114, pp.7426-7431
The anti-mycobacterial activity of the cytochrome bcc inhibitor Q203 can be enhanced by small-molecule inhibition of cytochrome bd, Sci Rep, vol.8, p.29422632, 2018. ,
Targeting the Mycobacterium ulcerans cytochrome bc1:aa3 for the treatment of Buruli ulcer, Nature Comm, vol.9, p.5370, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01975358
The compound TB47 is highly bactericidal against Mycobacterium ulcerans in a Buruli ulcer mouse model, Nature Comm, vol.10, p.524, 2019. ,
Shortening Buruli ulcer treatment with combination therapy targeting the respiratory chain and exploiting M. ulcerans gene decay, Antimicrob Agents Chemother, vol.63, pp.426-427, 2019. ,